Aelix Therapeutics, SL

Aelix Therapeutics, SL

Constitution date: 11/01/2015 Researchers: Christian Brander, Beatriz Mothe, Bonaventura Clotet

Aelix Therapeutics, based in Barcelona, is a spin-off of the HIVACAT vaccine research consortium. The company focuses on the discovery and development of immunotherapies against HIV infection. A first round of funding (11.5 million euros) was closed in January 2016. A phase II proof-of-concept clinical trial using the HTI immunogen as a therapeutic vaccine in people with HIV infection is foreseen to be completed by 2020. 

Read the news on the Aelix Therapeutics constitution. 

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

Obra Social - Fundació 'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

In cooperation with: